宫颈腺癌和子宫内膜腺癌中hr-HPV(16/18)DNA和p16,Vimentin,ER,PR表达组型的检测及鉴别诊断价值 Value of hr-HPV(16/18)DNA Detection and Expression Patterns of a Four-Marker(p16,vimentin,ER and PR)Panel in the Differential Diagnosis of Primary Endocervical and Endometrial Adenocarcinomas
Ansari-Lari MA,Staebler A,Zaino RJ,et al.Distinction of endocervical and endometrial adenocarcinomas:immunohistochemical p16 expression correlated with human papillomavirus(HPV)DNA detection[J].Am J Surg Pathol,2004,28(2):160-167.
[2]
Semczuk A,Miturski R,Skomra D,et al.Expression of the cell-cycle regulatoryproteins(pRb,cyclin D1,p16INK4A and cdk4)in human endometrial cancer:correlation with clinicopathological feature[J].Arch Gynecol Obstet,2004,269(2):104-110.
[3]
O’Neill CJ,McCluggage WG.p16expression in the female genital tract and its value in diagnosis[J].Adv Anat Pathol,2006,13(1):8-15.
[4]
Jones MW,Onisko A,Dabbs DJ,et al.Immunohistochemistry and HPV in situ hybridization in pathologic distinction between endocervical and endometrial adenocarcinoma:comparative tissue microarray study of 76tumors[J].Int J Gynecol Cancer,2013,23(2):380-384.
[5]
Liao CL,Lee MY,Tyan YS,et al.Progesterone receptor does not improve the performance andtest effectiveness of the conventional 3-maeker panel,consisting of estrogen receptor,vimentin and carcinoembryonic antigen in distinquishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension Study[J].J Transl Med,2009,7:37.
[6]
Giatromanolaki A,Sivridis E,Papazoglou D,et al.Human papillomavirus in endometrial adenocarcinomas:infectious agent or a mere“passenger”[J]?Infect Dis Obstet Gynecol,2007,2007:60 549.
Plunkett M,Brestovac B,Thompson J,et al.The value of HPV DNA typing in the distinction between adenocarcinoma of endocervical and endometrial origin[J].Pathology,2003,35(5):397-401.
[9]
Ogura K,Ishi K,Suzuki F,et al.Distribution of human papillomavirus types in different histological subtypes of cervical adenocarcinoma[J].Coll Antropol,2007,31(Suppl 2):97-102.
[10]
Zielinski GD,Snijders PJ,Rozendaal L,et al.The presence of high-risk HPV combined with specific p53and p16INK 4 Aexpression patterns points to highrisk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix[J].J Pathol,2003,201(4):535-543.
[11]
Yaziji H,Gown AM.Immunohistochemical analysis of gynecologic tumors[J].Int J Gynecol Pathol,2001,20(1):64-78.
[12]
Mylonas I,Jeschke U,Shabani N,et al.Normal and malignant human endometriumexpress immunohistochemically estrogen receptor alpha(ER-alpha),estrogen receptor beta(ER-beta)and progesterone receptor(PR)[J].Anticancer Res,2005,25(3A):1 679-1 686.
[13]
Han CP,LeeMY,Kok LF,et al.Adding the p16INK4a-marker to the traditional three-marker(ER/Vim/CEA)panel engenders no supplemental benefit in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study[J].Int J Gynecol Pathol,2009,28(5):489-496.
[14]
McCluggage WG.Immunohistochemistry as a diagnostic aid in cervical pathology[J].Pathology,2007,39(1):97-111.
[15]
Yemelyanova A,Vang R,Seidman JD,et al.Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas.Utility of HPV DNA detection and immunohistochemical expression of p16and hormone receptors to confirm the cervical origin of the corpus tumor[J].Am J Surg Pathol,2009,33(6):914-924.
[16]
McCluggage WG,Jenkins D.p16immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma[J].Int J Gynecol Pathol,2003,22(3):231-235.
[17]
Esheba GE.ProExC is a novel marker for distinguishing between primary endometrial and endocervical adenocarcinomas[J].J Egypt Natl Cancer Inst,2013,25(2):87-93.
[18]
Park TW,Zivanovic O,Theuerkauf I,et al.The diagnostic utility of human papilloma virus-testing in combination with immunohistochemistry in advanced gynaecologic pelvic tumours:a new diagnostic approach[J].Int J Oncol,2004,24(4):829-836.
Kong CS,Beck AH,Longacre TA.A panel of 3markers including p16,ProExC,or HPV SH is optimal for distinguishing between primary endometrial and endocervical denocarcinomas[J].Am J Surg Pathol,2010,34(7):915-926.
